Phio Pharmaceuticals Corp
Veridion Score
BETAMEDIUM CONF · 5/6 factorsComposite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is PHIO moving today?
Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
PHIO overview
Related filings and maps
Congress activity in PHIO
No receipt-qualified Congressional disclosure is present for PHIO in the cached public ledger.
PHIO contract awards, year to date.
Public federal awards linked to this ticker.
PHIO lobbying filings, year to date.
Registered lobbying filings matched to Phio Pharmaceuticals Corp.